New fabry drug shows promise in small switch study

NCT ID NCT05843916

First seen Feb 25, 2026 · Last updated May 15, 2026 · Updated 12 times

Summary

This study tested a new, similar version of the drug agalsidase beta (called AGA BETA BS) in 20 people with Fabry disease who were already doing well on the standard drug Fabrazyme. The goal was to see if switching to the new drug kept their disease marker (Lyso-Gb3) at the same low level after 6 months. The study was completed and compared the new drug's safety and effectiveness to the standard treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FABRY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Centro Médico Santa María de la Salud

    San Isidro, Buenos Aires, 1642, Argentina

  • Centro Oncológico Riojano Integral

    La Rioja, F5300, Argentina

  • Clínica Universitaria Reina Fabiola

    Córdoba, X5004, Argentina

  • Instituto de Investigaciones Clínicas Quilmes

    Buenos Aires, Argentina

  • Instituto de Nefrología Pergamino S.R.L

    Pergamino, Buenos Aires, 2700, Argentina

Conditions

Explore the condition pages connected to this study.